Document Detail


Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling.
MedLine Citation:
PMID:  19756559     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
PURPOSE: To evaluate the effects of CYP2C19 and CYP2C9 genotypes on the pharmacokinetic variability of valproic acid (VPA) in epileptic patients using a population pharmacokinetic (PPK) approach.
METHODS: VPA concentrations were measured in 287 epileptic patients, who were genotyped for CYP2C19*2/*3 and CYP2C9*3. Patients who were on monotherapy with VPA were divided into two groups, a PPK-model group (n = 177) and a PPK-valid group (n = 110). The PPK parameter values for VPA were calculated in the PPK-model group by using the NONMEM software. Ultimately, a biological model and a final model were established. Each model was then used to independently predict the concentrations of the PPK-valid group to validate the two models.
RESULTS: There was a significant effect of the CYP2C19 and CYP2C9 genotypes on the pharmacokinetic (PK) variability (P < 0.01) in the final PPK model of CL/F. The interindividual CL was calculated according to the final model: CL/F = 0.0951 x (1 + e(0.0267 x (3 - genotype))) + 0.0071 x age (L/h). The coefficient of variation (CV) (omega CL/F) of the final model was 29.3%, while that of the biological model was 31.7%. Based on the genotype, the individual PK parameters can be calculated more accurately than before.
CONCLUSION: The CYP2C19 and CYP2C9 genotypes significantly influenced the PK variability of VPA, as quantified by NONMEM software.
Authors:
Dechun Jiang; Xiangrong Bai; Qingxia Zhang; Wei Lu; Yuqin Wang; Lin Li; Markus Müller
Related Documents :
23134689 - A nonparametric bayesian approach for clustering bisulfate-based dna methylation profiles.
21967439 - Are relationships between pollen-ovule ratio and pollen and seed size explained by sex ...
6668559 - Adaptive control of theophylline therapy: importance of blood sampling times.
9825269 - Using gaussian-like input rate function in the two-compartment model. formulation and a...
15561849 - Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients thr...
7399709 - The pharmacokinetic basis of optimal antibiotic dosage.
1925159 - Estimating departure from normality.
22970069 - Effective connectivity between superior temporal gyrus and heschl's gyrus during white ...
16615059 - Methodology of detailed dosimetry and treatment of uncertainty and variations for in vi...
Publication Detail:
Type:  Journal Article     Date:  2009-09-16
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  65     ISSN:  1432-1041     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2010-01-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1187-93     Citation Subset:  IM    
Affiliation:
Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile o...
Next Document:  Endovascular stent-assisted thrombolysis in acute occlusive carotid artery dissection.